Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Dr. Reddy’s Laboratories Limited (DRL) has entered into an exclusive distribution partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across private markets in the country.

The pact is aimed at expanding the availability of Sanofi’s vaccine brands, both paediatric and adult, within private markets in India. 

ALSO READ: AstraZeneca bets on next-generation cancer therapy with $2 bn Fusion deal
 

It comes a day after Sanofi India announced a separate partnership with Cipla to boost access to Sanofi's Central Nervous System (CNS) medications across India.

Under the terms of the agreement, DRL will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel, and Avaxim 80U.

These brands have collectively generated approximately Rs 426 crore in sales as of IQVIA MAT February 2024. Sanofi will continue to retain ownership, manufacture, and import these brands into the country.

Speaking on the pact, Preeti Futnani, General Manager India for Vaccines at Sanofi, said: “Vaccine confidence has reached its highest in India in the last few years. Yet, there is much to be done for the rest of the country’s large unvaccinated cohort. To expand our geographic reach, we’re pleased to partner with Dr. Reddy for exclusive distribution and promotion.”

The portfolio of vaccine brands includes Hexaxim and Pentaxim, which are indicated for primary and booster vaccination of infants and toddlers against diseases such as Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, and bacterial diseases caused by Haemophilus influenzae.